Q1 EPS Forecast for Soleno Therapeutics Lowered by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities researchers at Lifesci Capital lowered their Q1 2025 earnings estimates for Soleno Therapeutics in a research note issued to investors on Thursday, March 27th. Lifesci Capital analyst M. Belghiti now anticipates that the company will earn ($1.46) per share for the quarter, down from their previous forecast of ($1.43). Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics' Q2 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.84) EPS, Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.25 EPS, Q4 2026 earnings at $0.32 EPS and FY2026 earnings at ($0.47) EPS.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.41).

Several other research analysts have also issued reports on SLNO. HC Wainwright raised their target price on shares of Soleno Therapeutics from $70.00 to $100.00 and gave the company a "buy" rating in a research note on Monday. Robert W. Baird raised their price objective on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Laidlaw upped their target price on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Cantor Fitzgerald increased their price target on Soleno Therapeutics from $67.00 to $123.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, UBS Group set a $105.00 price objective on Soleno Therapeutics in a research note on Thursday, March 27th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $99.63.

Remove Ads

Soleno Therapeutics Stock Down 2.0 %

SLNO stock traded down $1.51 during midday trading on Monday, reaching $72.16. The stock had a trading volume of 1,178,033 shares, compared to its average volume of 666,433. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of -21.73 and a beta of -2.29. Soleno Therapeutics has a twelve month low of $36.61 and a twelve month high of $74.00. The business has a fifty day simple moving average of $50.80 and a two-hundred day simple moving average of $50.65.

Insider Transactions at Soleno Therapeutics

In related news, insider Patricia C. Hirano sold 128,653 shares of the firm's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the sale, the insider now directly owns 55,789 shares in the company, valued at $3,811,504.48. This trade represents a 69.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Michael F. Huang sold 14,583 shares of the business's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $69.51, for a total transaction of $1,013,664.33. Following the completion of the sale, the vice president now directly owns 36,817 shares in the company, valued at $2,559,149.67. This represents a 28.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 945,012 shares of company stock valued at $64,166,842 over the last 90 days. 12.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. AlphaQuest LLC lifted its stake in Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock valued at $32,000 after acquiring an additional 658 shares in the last quarter. US Bancorp DE bought a new stake in shares of Soleno Therapeutics in the fourth quarter worth $34,000. Avanza Fonder AB bought a new stake in Soleno Therapeutics during the 4th quarter worth about $76,000. Springhill Fund Asset Management HK Co Ltd acquired a new position in Soleno Therapeutics during the fourth quarter worth $81,000. Finally, Avior Wealth Management LLC bought a new stake in Soleno Therapeutics during the fourth quarter worth $89,000. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.